

NeuroNEXT Network

Standard Operating Procedure (SOP)




Quality Management

Version 3.0

SOP NN QA 802

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

<p>Signature and Date:</p> <p>DocuSigned by Christopher Coffey</p> <p> I approve this document 16-Feb-2023 11:01:53 AM PST</p> <p>16-Feb-2023</p> <p>C68AC8DD80334CF982AED1200765F147</p>
<p>Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)</p>
<p>Signature and Date:</p> <p>DocuSigned by Merit Cudkowicz</p> <p> I approve this document 17-Feb-2023 8:30:31 AM EST</p> <p>17-Feb-2023</p> <p>9F8FE4180E504C6AB0A67B835E80C644</p>
<p>Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)</p>
<p>Signature and Date:</p> <p>DocuSigned by Marianne Chase</p> <p> I approve this document 17-Feb-2023 1:38:17 PM EST</p> <p>17-Feb-2023</p> <p>58FE690F6BCA4F2390E3DA15BCE3F578</p>

Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

Signature and Date:

DocuSigned by DIXIE ECKLUND
 | I approve this document
17-Feb-2023 | 4:06:04 PM PST
7006AF622EFC40B6A067A08EC02591B6

17-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

DocuSigned by Stacey Grabert
 | I approve this document
22-Feb-2023 | 11:14:03 AM EST
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon
 | I approve this document
21-Feb-2023 | 6:41:48 AM PST
72C6AAFD8CC4485582ACA0700072901A

21-Feb-2023

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

NN QA 802

NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR QUALITY MANAGEMENT

1. POLICY

The NeuroNEXT Network Data Coordinating Center (DCC) and Clinical Coordinating Center (CCC) will oversee Quality Management (QM) activities for all NeuroNEXT clinical trials. These activities help to ensure that all study-related activities meet Quality Assurance (QA) and Quality Control (QC) standards that are founded in Good Clinical Practices (GCP) and first principles of sound scientific and statistical research.

The DCC and/or CCC perform the following QM activities for the Network:

- defining areas of quality oversight;
- developing a comprehensive NeuroNEXT Network Quality Management Plan;
- developing quality improvement strategies, methods, reports, and tools (as required for a study);
- participating in the development, periodic review, and revision of NeuroNEXT Network Standard Operating Procedures (SOPs);
- reviewing, approving, and overseeing the development of Clinical Study Site (CSS or 'Site') SOPs as applicable;
- evaluating adherence to Network SOPs;
- conducting comprehensive training and re-training (as needed) of all CCC, DCC, and CSS study personnel on the study protocol, procedures, GCP, AE/SAE reporting, outcome measures, investigational product (IP) management, data collection/data handling, and proper study conduct;
- developing appropriate monitoring procedures to evaluate program effectiveness, ensure data safety and integrity, and maintain compliance with GCP, FDA regulations, and NeuroNEXT protocol directives;
- conducting routine monitoring and study close-out visits to ensure the quality, integrity, and completeness of study data;
- managing and tracking the reporting and coding of Adverse Events and Serious Adverse Events;
- determining CSS performance goals and metrics, assessing CSS performance and progress toward recruitment and retention goals, and assisting CSS with developing Corrective Action and Preventative Action (CAPA) plans and resolving performance issues;
- evaluating reports to assess performance metrics and to identify performance issues, if applicable to a study;
- implementing data quality procedures for evaluating data collection, data management, information technology, and statistical analysis activities to ensure data quality;
- verifying that applicable NeuroNEXT electronic data systems are 21 CFR Part 11 compliant;
- performing periodic assessments of IP management processes at CSS;
- conducting routine internal reviews of the Site Regulatory Files to ensure completeness and compliance with applicable federal regulations.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and

procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

The CCC Quality Assurance (QA) Team is responsible for overseeing QM activities for the NeuroNEXT Network, and for assessing adherence to Network SOPs and study protocols to assure quality performance.

4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 11	Electronic Records; Electronic Signatures
21 CFR 50	Protection of Human Subjects
ICH E6, 2.13	The Principles of ICH GCP
ICH E6, 5.1	Quality Assurance and Quality Control
ICH E6, 5.19	Audit
ICH E6, 5.20	Noncompliance
FDA	Compliance Policy Guide 7151.02

5. REFERENCES TO OTHER APPLICABLE SOPS

This SOP applies to all NeuroNEXT Network SOPs.

6. ATTACHMENTS AND REFERENCES

NN QA 802 - A	Document History
---------------	------------------

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CAPA	Corrective Action and Preventative Action
CCC	Clinical Coordinating Center at Massachusetts General Hospital
CFR	Code of Federal Regulations
CSS	Clinical Study Site(s)
DCC	Data Coordinating Center at The University of Iowa
FDA	Food and Drug Administration
GCP	Good Clinical Practices
ICH	International Conference on Harmonisation
IP	Investigational Product
PPI	Protocol Principal Investigator
QA	Quality Assurance: refers to a scheduled program of systematic monitoring that includes the creation and maintenance of SOPs, and objective reviews and quality improvement evaluations of targeted clinical trial areas and activities
QC	Quality Control: refers to day-to-day operational checks and activities that are undertaken to ensure that the quality requirements of the clinical trial are being met, and that SOPs are being followed
QM	Quality Management: refers to a system of oversight and review of QA processes and QC procedures

SAE Serious Adverse Event
 SOP Standard Operating Procedure

8. SPECIFIC PROCEDURES

A. Quality Management Overview

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC and CCC Leadership, CCC QA	Define areas of quality oversight, goals, and metrics for the NeuroNEXT Network.		
2.	CCC QA	Develop and maintain a comprehensive Quality Management Plan for the NeuroNEXT Network that includes areas of Quality Management oversight described in the sections below, and that describes a plan for: <ul style="list-style-type: none"> • implementing corrective actions • resolving quality or performance issues • follow-up to ensure resolution. 		
3.	DCC and CCC Leadership	Review and approve the comprehensive Quality Management Plan.		
4.	CCC, DCC	Create checklists, programs, reports, and other tools to assist with quality processes (as required or applicable to a study).		
5.	Site Support Team and Study Team	Evaluate reports to assess performance metrics and to identify performance issues.		

B. Network Standard Operating Procedures

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC and CCC SOP Development Committee	Collaborate to develop SOPs for the NeuroNEXT Network according to procedures described in SOP NN GA 101.		NN GA 101
2.	DCC and CCC SOP Development Committee	Review, revise, approve, and re-version NeuroNEXT Network SOPs as needed.		NN GA 101 NN GA 103

C. Clinical Study Site Standard Operating Procedures

#	Who	Task	Attachment/ Reference	Related SOP
1.	Site SOP Team	Collaborate to develop SOPs that apply to all NeuroNEXT Network CSS.		NN GA 101 NN GA 103
2.	Site SOP Development Committee	Finalize Site SOPs, and submit to DCC, CCC for approval and signatures.		NN GA 101
3.	Site SOP Development Committee	Review, revise, approve, and re-version NeuroNEXT Network Site SOPs as needed.		NN GA 101 NN GA 103

D. Areas of Quality Oversight

#	Who	Task	Attachment/ Reference	Related SOP
1.	CCC and DCC	<p>Training</p> <p>Conduct and document training for study personnel that includes, but is not limited to, the following areas:</p> <ul style="list-style-type: none"> • Study protocol, procedures, and proper study conduct • GCP • Investigational product management • Outcome measures • AE/SAE reporting • Data Collection and Data Handling <p>Perform periodic checks of training records to ensure completeness and compliance with SOPs.</p>		NN SS 402 NN SS 403 NN SS 404 NN PM 504 NN PM 505 NN SM 602 NN DM 1005
2.	DCC	<p>CSS Monitoring</p> <p>Conduct scheduled interim monitoring and final study close-out monitoring.</p> <ul style="list-style-type: none"> • DCC: perform comparisons of study data listings with source documents as detailed in the study Monitoring Plan, and as described in SOPs NN SS 403 and NN SS 405. 		NN SS 403 NN SS 405
3.	DCC	<p>Safety Reporting and Management</p> <p>Manage and track the reporting and coding of Adverse Events and Serious Adverse Events for each NeuroNEXT study.</p>		NN RA 206
4.	Site Support Team and Study Team	<p>Site Performance</p> <p>Create CSS performance goals and metrics, identify performance issues, and assist CSS in developing CAPA plans and resolving performance issues, or determine criteria for CSS termination, as described in SOPs NN SS 404 and NN SS 406.</p>		NN SS 404 NN SS 406

#	Who	Task	Attachment/ Reference	Related SOP
5.	NeuroNEXT Recruitment and Retention Committee, CCC, DCC, PPI	<p>Recruitment and Retention</p> <p>Collaborate to develop a Recruitment and Retention Plan for each NeuroNEXT study that may include:</p> <ul style="list-style-type: none"> metrics and goals for CSS enrollments methods and reports for tracking recruitment and retention incentives for CSS to reach their goals. 		NN SM 603
6.	Study Team	<p>Reports</p> <p>Generate and review reports, as appropriate and applicable to a study, to evaluate program effectiveness, assess implementation of quality measures and compliance with data quality objectives, and to identify areas for improvement.</p>		
7.	DCC	<p>NeuroNEXT Network User Access</p> <p>Perform periodic reviews of CCC, DCC, and CSS User Access records to ensure that current NeuroNEXT personnel are assigned appropriate database and website access rights and roles, and that NeuroNEXT personnel who have left the Network no longer have NeuroNEXT User Access rights or roles.</p>		NN CS 704
8.	DCC QM Lead or designee	<p>Data Systems and Data Management</p> <p>Conduct periodic random reviews of Data Management processes and NeuroNEXT data system development documentation to assess compliance with NeuroNEXT SOPs, 21 CFR Part 11, and other federal regulations governing data quality, security, and electronic systems, and to check for adequate documentation.</p>		NN CS 701 NN CS 702 NN CS 703 NN CS 704 NN CS 705 NN CS 706 NN DM 1004 NN DM 1005
9.	DCC QM Lead or designee	<p>Biostatistics</p> <p>Perform periodic, random evaluations of Biostatistics reports for compliance with Network SOPs and to check for adequate documentation.</p>		
10.	Study Team and IP distributor	<p>Investigational Product (IP) Management</p> <p>Perform periodic assessments of investigational product management processes at CSS to determine if standardization or quality improvements are needed or desirable.</p>		NN PM 505
11.	CCC and/or Sponsor	<p>Site Regulatory Files</p> <ul style="list-style-type: none"> CCC: Perform QC checks of regulatory documents and reports to be submitted to FDA or other applicable regulatory authorities. Sponsor and/or CCC: Perform periodic scheduled internal reviews of the Site Regulatory Files for each NeuroNEXT study. 		NN RA 201

Certificate Of Completion

Envelope Id: 3DD4BBA97C3D4D4897C07D6CE93D0142 Status: Completed
Subject: Complete with DocuSign: NN QA 802 Quality Management v3.0.docx
Source Envelope:
Document Pages: 7 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 24.62.91.235
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/16/2023 9:23:16 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey
christopher-coffey@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

Signature

Christopher Coffey

Timestamp

Sent: 2/16/2023 9:29:08 AM
Viewed: 2/16/2023 2:01:42 PM
Signed: 2/16/2023 2:01:55 PM

Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/16/2023 2:01:42 PM
ID: 6a976f11-5545-40a5-ab04-a12cf6d8401e

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
17-Feb-2023 | 4:06:04 PM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/16/2023 9:29:09 AM
Viewed: 2/17/2023 7:05:27 PM
Signed: 2/17/2023 7:06:06 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/17/2023 7:05:27 PM
ID: e0b502c8-aeac-458b-b60d-56a3a8aeb97d

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Joan Ohayon
ohayonj@ninds.nih.gov
Security Level: Email, Account Authentication (Required)

Joan Ohayon

Sent: 2/16/2023 9:29:10 AM
Resent: 2/21/2023 8:26:05 AM
Viewed: 2/21/2023 9:41:36 AM
Signed: 2/21/2023 9:41:51 AM

Signature Adoption: Pre-selected Style
Signature ID:
72C6AAFD-8CC4-4855-82AC-A0700072901A
Using IP Address: 156.40.137.188

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/13/2023 2:03:22 PM
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase
MCHASE@mgh.harvard.edu
Sr Director, Clinical Trial Operations
Insight OBO The Massachusetts General Hospital
Security Level: Email, Account Authentication (Required), Logged in

Marianne Chase


Sent: 2/16/2023 9:29:09 AM
Viewed: 2/17/2023 1:37:57 PM
Signed: 2/17/2023 1:38:21 PM

Signature Adoption: Pre-selected Style
Signature ID:
58FE690F-6BCA-4F23-90E3-DA15BCE3F578
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Merit Cudkowicz
cudkowicz.merit@mgh.harvard.edu
Chief of Neurology
Security Level: Email, Account Authentication (Required), Logged in

DocuSigned by Merit Cudkowicz

I approve this document
17-Feb-2023 | 8:30:31 AM EST
9F8FE4180E504C6AB0A67B835E80C644


Sent: 2/16/2023 9:29:10 AM
Viewed: 2/17/2023 8:30:22 AM
Signed: 2/17/2023 8:30:34 AM

Signature Adoption: Pre-selected Style
Signature ID:
9F8FE418-0E50-4C6A-B0A6-7B835E80C644
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/17/2023 8:30:22 AM
ID: 237abe28-e58b-44f9-96b1-caf3f0f2e946

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/16/2023 9:29:10 AM Resent: 2/21/2023 8:26:05 AM Viewed: 2/22/2023 11:13:52 AM Signed: 2/22/2023 11:14:06 AM
---	--	--

Electronic Record and Signature Disclosure:
Accepted: 7/20/2020 8:50:14 AM
ID: 5ebadf74-e399-40fd-be82-9c7ca902061b

In Person Signer Events	Signature	Timestamp
-------------------------	-----------	-----------

Editor Delivery Events	Status	Timestamp
------------------------	--------	-----------

Agent Delivery Events	Status	Timestamp
-----------------------	--------	-----------

Intermediary Delivery Events	Status	Timestamp
------------------------------	--------	-----------

Certified Delivery Events	Status	Timestamp
---------------------------	--------	-----------

Carbon Copy Events	Status	Timestamp
--------------------	--------	-----------

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
-------------------------	--------	------------

Envelope Sent	Hashed/Encrypted	2/16/2023 9:29:10 AM
Certified Delivered	Security Checked	2/22/2023 11:13:52 AM
Signing Complete	Security Checked	2/22/2023 11:14:06 AM
Completed	Security Checked	2/22/2023 11:14:06 AM

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.